SBI Securities’s Seres Therapeutics MCRB Stock Holding History

SBI Securities’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33K	Buy	4,182 +700	+20%	+$5.33K	﹤0.01%	1332
2026 Q1	$30.9K	Hold	3,482	–	–	﹤0.01%	1290
2025 Q4	$51.8K	Hold	3,482	–	–	﹤0.01%	1071
2025 Q3	$67K	Hold	3,482	–	–	﹤0.01%	975
2025 Q2	$38.7K	Sell	3,482 -1	-0%	-$9	﹤0.01%	1153
2025 Q1	$48.8K	Buy	3,483 +2,400	+222%	+$37.6K	﹤0.01%	989
2024 Q4	$18K	Buy	+1,083	New	+$17.6K	﹤0.01%	1403

Other funds holding MCRB

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

RIAS

Rachor Investment Advisory Services Linden, Michigan $203M AUM

WTC

WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return

SBI Securities's MCRB Position: Q2 2026 in Review

SBI Securities increased its Seres Therapeutics (MCRB) stake by 20% in Q2 2026, buying an estimated $5.33K and bringing the position to 4,182 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #1332.

SBI Securities first reported a position in MCRB in Q4 2024 and has held it in 7 quarters since. The position peaked at $67K in Q3 2025. 4 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

SBI Securities held 4,182 shares of Seres Therapeutics worth $33K as of Q2 2026.
SBI Securities bought 700 Seres Therapeutics shares in Q2 2026, an estimated $5.33K.
Seres Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1332 holding.
SBI Securities first reported a position in Seres Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Seres Therapeutics position peaked at $67K in Q3 2025.
4 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.